Form 8-K - Current report:
SEC Accession No. 0001628280-25-029678
Filing Date
2025-06-05
Accepted
2025-06-05 16:32:45
Documents
12
Period of Report
2025-06-05
Items
Item 5.07: Submission of Matters to a Vote of Security Holders

Document Format Files

Seq Description Document Type Size
1 8-K vnda-20250605.htm   iXBRL 8-K 45470
  Complete submission text file 0001628280-25-029678.txt   166461

Data Files

Seq Description Document Type Size
2 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT vnda-20250605.xsd EX-101.SCH 1834
3 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT vnda-20250605_lab.xml EX-101.LAB 22548
4 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT vnda-20250605_pre.xml EX-101.PRE 13656
14 EXTRACTED XBRL INSTANCE DOCUMENT vnda-20250605_htm.xml XML 2947
Mailing Address 2200 PENNSYLVANIA AVE NW SUITE 300E WASHINGTON DC 20037
Business Address 2200 PENNSYLVANIA AVE NW SUITE 300E WASHINGTON DC 20037 202-734-3400
Vanda Pharmaceuticals Inc. (Filer) CIK: 0001347178 (see all company filings)

EIN.: 030491827 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-34186 | Film No.: 251027591
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)